Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloGen-LI for Spinal Stenosis Symptoms
NCT02932020Withdrawn
- Sponsor
- University of Southern California
- Start
- Oct 2016
- Primary completion
- Sep 2017
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Randomised, single-blind trial of AlloGen-LI in spinal stenosis and intervertebral disc displacement (2 arms), sponsored by University of Southern California. Primary endpoint: Pain Reduction at 12 weeks. Planned start Oct 2016; status: withdrawn.
02
Drugs
AlloGen-LI
03
Conditions
spinal stenosisintervertebral disc displacement
Beyond the preview
Go deeper on NCT02932020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932020.